7.3 Endocrine Control of Calcium and Phosphate
Key Takeaways
- Ionised calcium is normally 1.10 to 1.35 mmol/L, total serum calcium 2.20 to 2.60 mmol/L and phosphate 0.8 to 1.5 mmol/L.
- Parathyroid hormone raises calcium and lowers phosphate by acting on osteoblast PTH1R receptors, renal reabsorption and renal 1-alpha-hydroxylase.
- Calcitriol raises both calcium and phosphate by increasing intestinal absorption through TRPV6 and calbindin.
- FGF-23 from osteocytes lowers phosphate by suppressing NaPi-IIa and NaPi-IIc cotransporters and renal 1-alpha-hydroxylase.
- Vitamin D deficiency produces rickets in growing bone and osteomalacia in mature bone.
4. Endocrine Regulation of Systemic Calcium and Phosphate Homeostasis
Normal neuromuscular transmission, blood coagulation, enzyme activation, and skeletal structural integrity require tight regulation of extracellular ionized calcium ([Ca²⁺]: 1.10–1.35 mmol/L; total serum calcium: 2.20–2.60 mmol/L) and inorganic phosphate (0.8–1.5 mmol/L).
Parathyroid Hormone (PTH)
- An 84-amino acid peptide synthesized by the chief cells of the parathyroid glands.
- Released in response to minute decreases in extracellular ionized calcium detected by the G-protein coupled Calcium-Sensing Receptor (CaSR) on parathyroid cell membranes.
- Actions:
- Bone: Binds to PTH1R receptors on osteoblasts (osteoclasts lack PTH receptors). Osteoblasts respond by upregulating membrane-bound RANKL and downregulating OPG, stimulating osteoclast-mediated bone resorption to rapidly release calcium and phosphate into the circulation.
- Kidney: Stimulates calcium reabsorption in the distal convoluted tubule. Simultaneously, it inhibits phosphate reabsorption in the proximal convoluted tubule by internalizing NaPi-IIa cotransporters, causing massive phosphaturia. This prevents calcium-phosphate precipitation (Ca × PO₄ solubility product). Concurrently, PTH upregulates renal 1α-hydroxylase (CYP27B1).
- Net Effect: Elevates serum calcium (Ca²⁺↑); decreases serum phosphate (PO₄³⁻↓).
1,25-Dihydroxyvitamin D3 (Calcitriol)
- A steroid hormone derived from skin 7-dehydrocholesterol following UVB photolysis, which undergoes 25-hydroxylation in the liver (CYP2R1) and subsequent 1α-hydroxylation in the renal proximal tubule (CYP27B1, stimulated by PTH and inhibited by FGF-23).
- Actions:
- Intestine: Calcitriol binds the nuclear Vitamin D Receptor (VDR) in enterocytes, transcribing apical calcium channels (TRPV6), cytoplasmic calcium shuttle proteins (Calbindin-D9k), and basolateral extrusion pumps (PMCA1b). This dramatically increases active transcellular intestinal absorption of dietary calcium and phosphate.
- Bone: Synergizes with PTH to support osteoclastogenesis during hypocalcaemia, but is fundamentally essential for normal osteoblast function and mineralization of newly deposited osteoid. Severe deficiency causes rickets in children and osteomalacia in adults (failure of osteoid mineralization).
- Net Effect: Elevates both serum calcium (Ca²⁺↑) and serum phosphate (PO₄³⁻↑).
Calcitonin
- A 32-amino acid peptide synthesized by the parafollicular C-cells of the thyroid gland.
- Secreted in response to hypercalcaemia.
- Actions: Binds directly to calcitonin receptors expressed on mature osteoclasts, immediately halting motility, retracting the ruffled border, and detaching the sealing zone, rapidly arresting bone resorption.
- Net Effect: Decreases serum calcium (Ca²⁺↓) and phosphate (PO₄³⁻↓). In adult humans, calcitonin plays only a weak, secondary regulatory role compared to PTH and calcitriol.
Fibroblast Growth Factor 23 (FGF-23) — The Phosphatonin Axis
- A 251-amino acid endocrine peptide synthesized predominantly by osteocytes in response to elevated serum phosphate and elevated calcitriol.
- Actions: Acts on the renal proximal tubule, requiring the obligate transmembrane co-receptor α-Klotho.
- Downregulates NaPi-IIa and NaPi-IIc cotransporters, inducing profound renal phosphate excretion (phosphaturia).
- Directly suppresses renal 1α-hydroxylase (CYP27B1) and upregulates the catabolic 24-hydroxylase (CYP24A1), shutting down active calcitriol production to limit further intestinal phosphate absorption.
- Net Effect: Decreases serum phosphate (PO₄³⁻↓), preventing hyperphosphataemia and protecting against fatal vascular and ectopic soft-tissue calcification.
| Hormone | Principal Cellular Source | Primary Secretory Trigger | Target Organs | Primary Biological Action | Net Effect on Serum Minerals |
|---|---|---|---|---|---|
| PTH | Parathyroid chief cells | Hypocalcaemia (low ionized Ca²⁺) | Bone, Kidney | Resorbs bone, reabsorbs renal Ca²⁺, blocks renal PO₄³⁻, activates calcitriol | Ca²⁺↑, PO₄³⁻↓ |
| Calcitriol [1,25(OH)₂D₃] | Renal proximal tubule (CYP27B1) | Elevated PTH, hypophosphataemia | Intestine, Bone | Enhances active intestinal Ca²⁺ and PO₄³⁻ absorption | Ca²⁺↑, PO₄³⁻↑ |
| Calcitonin | Thyroid parafollicular C-cells | Hypercalcaemia | Bone osteoclasts | Inhibits osteoclastic ruffled border motility and resorption | Ca²⁺↓, PO₄³⁻↓ |
| FGF-23 | Mature bone osteocytes | Hyperphosphataemia, elevated calcitriol | Kidney (with α-Klotho) | Induces renal phosphate excretion, suppresses CYP27B1 | PO₄³⁻↓, Calcitriol ↓ |
Why Dentists Are Asked About Calcium Metabolism
The blueprint places calcium and phosphate homeostasis in Paper A because the dentition and jaws are among the first places systemic mineral disturbance becomes visible. Hyperparathyroidism — primary from a parathyroid adenoma, or secondary to chronic kidney disease — raises parathyroid hormone, increases osteoclastic resorption and produces the classic radiographic triad of generalised loss of lamina dura, a ground-glass trabecular pattern and, in advanced disease, well-defined radiolucent brown tumours that are histologically identical to central giant cell granuloma. The examinable point is that a giant cell lesion in the jaws obliges the clinician to exclude hyperparathyroidism by measuring serum calcium, phosphate and parathyroid hormone before treating the lesion as a local problem.
Hypoparathyroidism, most often iatrogenic after thyroid surgery, produces hypocalcaemia with paraesthesia, carpopedal spasm, Chvostek's and Trousseau's signs, and in children enamel hypoplasia and delayed eruption. Rickets and osteomalacia from vitamin D deficiency produce large pulp chambers with pulp horns extending to the amelodentinal junction, hypoplastic enamel and increased risk of spontaneous pulpal infection.
Drugs Acting on Bone Turnover
The therapeutic manipulation of this axis is directly examinable. Bisphosphonates bind hydroxyapatite and are internalised by osteoclasts, inhibiting the mevalonate pathway and inducing osteoclast apoptosis; they have a very long skeletal half-life, so risk persists long after the drug is stopped. Denosumab is a monoclonal antibody against RANKL that prevents osteoclast differentiation; its effect reverses within months of discontinuation because it is not incorporated into bone. Romosozumab inhibits sclerostin and is both anabolic and antiresorptive. All three are associated with medication-related osteonecrosis of the jaw, and the distinction in skeletal persistence between bisphosphonates and denosumab is exactly the kind of discriminating fact an SBA distractor set is built around.
At the molecular level, what is the primary biological mechanism by which osteoprotegerin (OPG) regulates alveolar bone remodelling?